UBS analyst Ashwani Verma raised the firm’s price target on Intra-Cellular to $80 from $74 and keeps a Buy rating on the shares. The firm said that the MDD mini-dive increases conviction in upcoming catalyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
- Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
- Biotech Alert: Searches spiking for these stocks today
- ‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protection
- Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update